IPHASE founded in 2018) is a high-tech enterprise focusing on bio-medicinal and life science research. Our scientific team is dedicated to providing high-quality innovative biological reagent products and related technical services for scientists through rich knowledge reserve and unremitting scientific exploration.

iPhase commenced operations in 2010 and launched its first ADMEs products for drug early screening.  iPhase has further expanded its product portfolios through robust investment and efforts in research and development of products used in in pharmacokinetics, pharmacology, microbiology, genotoxicity, immunology, and caner. Our products are validated by either peer-recognized in-house standards or international harmonized standards (e.g. OECD and ICH).

The core competencies and capabilities of iPhase are chemical- and bio-analysis, cytogenetics, DNA engineering, protein and antibody development, and immunoassay. Our Mission is to provide innovative reagents to innovative research.